Your browser doesn't support javascript.
loading
Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis.
Bronge, Mattias; Högelin, Klara Asplund; Thomas, Olivia G; Ruhrmann, Sabrina; Carvalho-Queiroz, Claudia; Nilsson, Ola B; Kaiser, Andreas; Zeitelhofer, Manuel; Holmgren, Erik; Linnerbauer, Mathias; Adzemovic, Milena Z; Hellström, Cecilia; Jelcic, Ivan; Liu, Hao; Nilsson, Peter; Hillert, Jan; Brundin, Lou; Fink, Katharina; Kockum, Ingrid; Tengvall, Katarina; Martin, Roland; Tegel, Hanna; Gräslund, Torbjörn; Al Nimer, Faiez; Guerreiro-Cacais, André Ortlieb; Khademi, Mohsen; Gafvelin, Guro; Olsson, Tomas; Grönlund, Hans.
Afiliação
  • Bronge M; Therapeutic Immune Design, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, 171 76 Stockholm, Sweden.
  • Högelin KA; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden.
  • Thomas OG; Therapeutic Immune Design, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, 171 76 Stockholm, Sweden.
  • Ruhrmann S; Therapeutic Immune Design, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, 171 76 Stockholm, Sweden.
  • Carvalho-Queiroz C; Therapeutic Immune Design, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, 171 76 Stockholm, Sweden.
  • Nilsson OB; Therapeutic Immune Design, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, 171 76 Stockholm, Sweden.
  • Kaiser A; Therapeutic Immune Design, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, 171 76 Stockholm, Sweden.
  • Zeitelhofer M; Division of Vascular Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden.
  • Holmgren E; Therapeutic Immune Design, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, 171 76 Stockholm, Sweden.
  • Linnerbauer M; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden.
  • Adzemovic MZ; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden.
  • Hellström C; Division of Affinity Proteomics, Department of Protein Science, SciLifeLab, KTH-Royal Institute of Technology, 171 65 Solna, Sweden.
  • Jelcic I; Neuroimmunology and MS Research Section (NIMS), Neurology Clinic, University of Zürich, University Hospital Zürich, 8091 Zürich, Switzerland.
  • Liu H; Department of Protein Science, KTH-Royal Institute of Technology, 114 21 Stockholm, Sweden.
  • Nilsson P; Division of Affinity Proteomics, Department of Protein Science, SciLifeLab, KTH-Royal Institute of Technology, 171 65 Solna, Sweden.
  • Hillert J; Department of Clinical Neuroscience, Division of Neurology, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden.
  • Brundin L; Department of Clinical Neuroscience, Division of Neurology, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden.
  • Fink K; Department of Clinical Neuroscience, Division of Neurology, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden.
  • Kockum I; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden.
  • Tengvall K; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden.
  • Martin R; Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, 752 37 Uppsala, Sweden.
  • Tegel H; Neuroimmunology and MS Research Section (NIMS), Neurology Clinic, University of Zürich, University Hospital Zürich, 8091 Zürich, Switzerland.
  • Gräslund T; Human Protein Atlas, Department of Protein Science, KTH-Royal Institute of Technology, Stockholm, Sweden.
  • Al Nimer F; Department of Protein Science, KTH-Royal Institute of Technology, 114 21 Stockholm, Sweden.
  • Guerreiro-Cacais AO; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden.
  • Khademi M; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden.
  • Gafvelin G; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden.
  • Olsson T; Therapeutic Immune Design, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, 171 76 Stockholm, Sweden.
  • Grönlund H; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden.
Sci Adv ; 8(17): eabn1823, 2022 Apr 29.
Article em En | MEDLINE | ID: mdl-35476434
ABSTRACT
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS), in which pathological T cells, likely autoimmune, play a key role. Despite its central importance, the autoantigen repertoire remains largely uncharacterized. Using a novel in vitro antigen delivery method combined with the Human Protein Atlas library, we screened for T cell autoreactivity against 63 CNS-expressed proteins. We identified four previously unreported autoantigens in MS fatty acid-binding protein 7, prokineticin-2, reticulon-3, and synaptosomal-associated protein 91, which were verified to induce interferon-γ responses in MS in two cohorts. Autoreactive profiles were heterogeneous, and reactivity to several autoantigens was MS-selective. Autoreactive T cells were predominantly CD4+ and human leukocyte antigen-DR restricted. Mouse immunization induced antigen-specific responses and CNS leukocyte infiltration. This represents one of the largest systematic efforts to date in the search for MS autoantigens, demonstrates the heterogeneity of autoreactive profiles, and highlights promising targets for future diagnostic tools and immunomodulatory therapies in MS.

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Sci Adv Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suécia

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Sci Adv Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suécia